Efficacy of tenofovir alafenamide in patients with chronic hepatitis B undergoing chronic hemodialysis and kidney transplantation: A real-world data study
Hepatology Forum · 2026 · 7 (4) · 313-318
DOI: 10.14744/hf.2026.38987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Forum, 2026. Verfasst von Abdullah Tokuc und 16 weiteren Autor:innen. Beteiligte Einrichtung: : Department of Gastroenterology, Antalya Kepez State Hospital, Antalya, Türkiye. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Aim: This study evaluated the efficacy and safety of tenofovir alafenamide (TAF) in chronic hepatitis B virus-infected patients undergoing chronic hemodialysis and kidney transplant recipients. Materials and Methods: Between January 2019 and January 2023, patients receiving TAF who were undergoing chronic hemodialysis or were kidney transplant recipients were included in a multicenter retrospective study at 17 tertiary care centers across Türkiye.
Results
A total of 58 patients were included (13 receiving hemodialysis and 45 kidney transplant recipients). The mean age of patients was 50.1±12.5 years, with a predominantly male gender (71%). At baseline, 19 patients were hepatitis B virus DNA-positive; 11 of whom were antiviral treatment-naïve. The virological response rate was 78.9% (15/19) at 12 months of TAF treatment and increased to 94.7% (18/19) by 24 months. Patients with elevated baseline alanine aminotransferase levels exhibited significant improvement after initiation of TAF. Overall, TAF was well tolerated throughout the study period, with no serious adverse events or drug discontinuations due to adverse effects.
Conclusion
TAF was associated with effective virological suppression and favorable biochemical response in patients with chronic HBV infection undergoing chronic hemodialysis and kidney transplant recipients. TAF was generally well tolerated in such patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- : Department of Gastroenterology, Antalya Kepez State Hospital, Antalya, Türkiye.
- : Department of Gastroenterology, Akdeniz University Faculty of Medicine, Antalya, Türkiye.
- : Department of Gastroenterology, Baskent University Faculty of Medicine, Ankara, Türkiye.
- : Department of Gastroenterology, Gaziantep University Faculty of Medicine, Gaziantep, Türkiye.
- : Department of Gastroenterology, Marmara University Faculty of Medicine, Istanbul, Türkiye.
- : Department of Gastroenterology, Ankara City Hospital, Ankara, Türkiye.
Zitieren
APA
Tokuc, A., Dincer, D., Etik, D. O., Yildirim, A. E., Mehdiyev, S., Ari, D., Cosar, A. M., Adanir, H., Gokcan, H., Yapali, S., Dilber, F., Kacar, S., Akdogan, M., Tozun, N., Boyacioglu, S., Idilman, R., & TASL Viral Hepatitis Special Interest Group (SIG) (2026). Efficacy of tenofovir alafenamide in patients with chronic hepatitis B undergoing chronic hemodialysis and kidney transplantation: A real-world data study. Hepatology Forum, 7(4), 313-318. https://doi.org/10.14744/hf.2026.38987
Vancouver
Tokuc A, Dincer D, Etik DO, Yildirim AE, Mehdiyev S, Ari D, et al. Efficacy of tenofovir alafenamide in patients with chronic hepatitis B undergoing chronic hemodialysis and kidney transplantation: A real-world data study. Hepatology Forum. 2026;7(4):313-318. doi:10.14744/hf.2026.38987
BibTeX
@article{Tokuc2026,
author = {Tokuc, Abdullah and Dincer, Dinc and Etik, Digdem Ozer and Yildirim, Abdullah Emre and Mehdiyev, Shahin and Ari, Derya and Cosar, Arif Mansur and Adanir, Haydar and Gokcan, Hale and Yapali, Suna and Dilber, Feyza and Kacar, Sabite and Akdogan, Meral and Tozun, Nurdan and Boyacioglu, Sedat and Idilman, Ramazan and TASL Viral Hepatitis Special Interest Group (SIG), TASL Viral Hepatitis Special Interest Group (SIG)},
title = {Efficacy of tenofovir alafenamide in patients with chronic hepatitis B undergoing chronic hemodialysis and kidney transplantation: A real-world data study},
journal = {Hepatology Forum},
year = {2026},
volume = {7},
number = {4},
pages = {313--318},
doi = {10.14744/hf.2026.38987}
}
EUVIMED